Open Access

Analysis of MAT3 gene expression in NSCLC

  • Shangen Zheng1,
  • Yuwen Du2,
  • Heying Chu3,
  • Xudong Chen4,
  • Ping Li3,
  • Yuanyuan Wang2,
  • Yunyun Ma2,
  • Huaqi Wang3,
  • Wenqiao Zang2,
  • Guojun Zhang3Email author and
  • Guoqiang Zhao2Email author
Diagnostic Pathology20138:166

DOI: 10.1186/1746-1596-8-166

Received: 26 August 2013

Accepted: 24 September 2013

Published: 9 October 2013

Abstract

Background

Many studies have suggested different roles of Metastasis-associated protein 3 (MAT3) in different types of human cancers. However, expression of MAT3 in primary lung cancer and its relationship with clinicopathological factors have not been examined and the biological roles of MTA3 in lung cancer cells are still unclear.

Methods

The expression of MAT3 mRNA and protein were detected with quantitative real-time RT-PCR and immunohistochemical methods in 118 NSCLC samples and corresponding non-neoplastic samples. Survival curves were made with follow-up data. The relations of the prognosis with clinical and pathological characteristics were analyzed.

Results

The expression level of MAT3 mRNA and the positive rate of MAT3 protein were significantly higher in NSCLC samples than that in non-neoplastic samples, and in NSCLC samples with lymph node metastasis than that in NSCLC samples without lymph node metastasis (P < 0.01). MAT3 mRNA expression level was a risk factor of lymph node metastasis in patients with NSCLC (P = 0.006). There were significant differences in survival curves between lymph node metastatic group and non-metastatic group (P = 0.000), among groups of MAT3 positive and negative (P = 0.000), among groups of TNM stage I, II and III (P = 0.000) and among groups of tumor status T1, T2 and T3T4 (P = 0.000); but no statistical significance between male patients and female patients (P = 0.516), between ≥60 years old patients and <60 years old patients (P = 0.133), between histology types adenocarcinoma and squamous cell carcinoma (P = 0.865) and between well differentiation and moderate-poor differentiation (P = 0.134). The level of MAT3 mRNA (P = 0.000) and protein (P = 0.000) were risk factors of survival.

Conclusion

Our study showed that MAT3 over-expression in NSCLC tissue, and MAT3 mRNA level is a risk factor of lymph node metastasis. The level of MAT3 mRNA and protein were risk factors of survival in patients with NSCLC. It suggested that this antigen could be used as a simple and efficient parameter with which to identify high-risk patients.

Virtual slides

The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5585901065503943.

Keywords

Non-small-cell lung cancers (NSCLC) MAT3 Gene expression

Introduction

Metastasis-associated protein 3 (MTA3) was originally found as a member of a small protein family (including MTA1, MTA2 and MTA3), which is a constituent of the Mi-2/nucleosome remodeling and deacetylase (NuRD) protein complex that regulates gene expression by altering chromatin structure and can facilitate cohesin loading onto DNA [18].

MTA3 was reported to participate in B lymphocyte development, in plasmacytoma cell lines, the overexpression of BCL6 (B-cell CLL/lymphoma 6) and MTA3 downregulated plasma cell differentiation genes [9]. Since then, however, the expression of MTA3 has been found reduced in breast cancer, endometrial cancer and ovarian cancer [1012]. MTA3 upregulation prevents epithelial-mesenchymal transition (EMT) by directly repressing Snail expression, thereby upregulating E-cadherin protein levels in breast cancer [8, 13]. Moreover, MTA3 was reported as an independent and unfavorable prognostic marker in uterine non-endometriod carcinoma [14]. These findings suggest that the expression of MTA3 is closely related to invasiveness, metastasis and prognosis of tumour.

Lung cancer is one of the leading causes of all cancer-related deaths worldwide and its incidence is increasing [15, 16]. The majority of diagnosed lung cancer cases are non-small-cell lung cancers (NSCLCs). Many previous studies showed the expression and functions of proteins, genes and enzymes in lung cancer [8, 17, 18]. However, expression of MTA3 mRNA and protein in primary lung cancer and its relationship with clinicopathological factors has not been examined and the biological roles of MTA3 in lung cancer cells are still unclear.

To explore the role of MTA3 in NSCLC, we analysed 118 cases of NSCLC patients retrospectively between 2001 and 2005, detected the expression of MTA3 mRNA and protein with real time RT-PCR and immunohistochemical methods, and explore the relationship between expression of MTA3 mRNA and protein and survival time.

Materials and methods

Clinical sample collection

Between 1.1.2001 and 31.7.2005, 118 patients with NSCLC were enrolled in this study from Wuhan General Hospital of Guangzhou Military and the First Affiliated Hospital of Zhengzhou University. Patients who had recurrent NSCLC or primary NSCLC but received chemoradiotherapy before surgical operation were excluded. Of the 118 patients, 59 were female and 59 were male. And there were 49 cases with lymph node metastasis, 69 cases without lymph node metastasis. We obtained paired NSCLC and adjacent non-tumor lung tissues (located more than 5 cm away from the tumors) from 118 patients who underwent primary surgical resection of NSCLC with informed consent. Both tumor and non-tumor samples were confirmed as such by pathological examinations. These samples were snap-frozen in liquid nitrogen after resection. This study was approved by the ethics committee of Zhengzhou University and informed consent was obtained from each patient (Table 1).
Table 1

Clinicopathologic characteristics of the 118 NSCLC cases

Parameter

Category

n

Gender

Male

59

Female

59

Age (years)

≥60

66

<60

52

Histology

Adeno

69

SCC

49

Differentiation

Well

46

Moderate -poor

72

Tumor stage

T1

39

T2

55

T3–4

24

TNM stage

I

52

II

42

III

24

Node status

Positive

49

Negative

69

Immunohistochemistry

The MTA3 protein was detected by a rabbit polyclonal antibody (Santa Cruz USA). The sections were stained with streptavidin peroxidase (SP) kit (Maixin Biotechnology Company, China), visualized with DAB coloration kit (Boaosen Company, China), followed by counterstaining of campeachy, dehydration, transparency and mounting [17]. All slides were evaluated by two different pathologists and then in conference in a blinded manner without any prior knowledge of the clinicopathological parameters. Negative controls of immunohistochemical reactions were performed by omitting the primary antibody. Replacement of primary antibody by PBS was used as blank control. Staining intensity was modified. Briefly, gray-scale digitized images were imported into the Optimas software (Optimas 6.0, Optimus Corp., Bothell, WA, USA). Control staining (without primary antibody) was used for the extraction of the background staining. In every case, control reactions were included, in which specific antibody was substituted by the Primary Mouse Negative Control.

Real-time fluorescent quantitative RT-PCR

MTA3 and GAPDH primers were designed according to MTA3 mRNA (NM_020744) and GAPDH mRNA (NM_002046) with Oligo 6.0 software. The sequences were as follows: MTA3 sense 5′ TATCAGGGGAAAGTGCAGTGTTG 3′, MTA3 antisense 5′-AACAGCATTTCTGGAATGTCTGC-3′, GAPDH sense 5′-GCAAATT CCATGGCACCGTCAAG-3′, GAPDH antisense 5′-GTGGTGAAGACGCCAG TGGACTC-3′. The length of fragments amplified by PCR with MTA3 primers and GAPDH primers were 183 bp and 151 bp, respectively. All the primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd. RNAs were extracted from 118 NSCLC samples with RNA extraction kit (Qiagen) and then cDNAs were synthetized by AMV (Promega). Aliquots of the reaction mixture were used for the qPCR amplification with the IQ5 system (Bio-Rad) using IQ SYBR Green Supermix (Bio-Rad). The PCR was run for 40 cycles of denaturation at 95°C for 15 sec, annealing at 55°C for 15 sec and elongation at 72°C for 15 sec. Gene expression was quantified by the comparative CT method, by normalizing CT values to the housekeeping gene GAPDH. After amplification, melting curve analysis was performed to ensure the specificity of the products.

Statistical analysis

Statistical analysis was performed using SPSS17.0 software. Data were expressed as means ± standard deviation (SD). Student’s t test was used in the comparison of mean between two samples. Fourfold table Chi square test was used in the comparison of ratios between two samples. Logistic analysis was used in the correlation of lymph node metastasis with MAT3 mRNA expression. The follow-up data was analyzed by the Kaplan-Meier method and log-rank test. Cox proportional hazards model were used in multivariate prognostic analysis. P values less than 0.05 were considered statistically significant.

Results

MTA3 mRNA is over-expressed in NSCLC samples and is a risk factor of lymph node metastasis

MTA3 mRNA is over-expressed in NSCLC samples and is a risk factor of lymph node metastasis. The relative expression level of MTA3 mRNA was significantly higher in NSCLC samples (118 samples, 0.2494 ±0.10361) than that in non-neoplastic samples(118 corresponding samples, 0.1578 ± 0.07694) (P = 0.002), and in NSCLC samples with lymph node metastasis(49 samples, 0.2810 ± 0.08593) than that in NSCLC samples without lymph node metastasis (69 samples, 0.2270 ± 0.10969) (P = 0.003) (Table 1). Logistic regression analysis indicated that the relative expression level of MTA3 mRNA was a risk factor of lymph node metastasis in the patients with NSCLC (Wald χ2 = 7.493, P = 0.006).

Positive rate of MTA3 protein is high in NSCLC samples and associated with lymph node metastasis

MTA3 showed positive immuno-reactivity mainly in nucleus and cytoplasms of the cells (Figure 1). The positive rate of MTA3 protein expression was significantly higher in NSCLC samples (59.32%, 70/118) than that in non-neoplastic samples (0.00%, 0/118), and in NSCLC samples with lymph node metastasis (79.59%, 39/49) was higher than that in NSCLC samples without lymph node metastasis (44.93%, 31/69) (P =0.000). Statistical differences were found between different ages (P = 0.038), differentiation (P = 0.001), tumor stage (P = 0.018) and TNM stage (P = 0.018) (Table 2). There were no statistical differences between different genders (P = 1.000) and histology (P = 0.849) (Table 2).
https://static-content.springer.com/image/art%3A10.1186%2F1746-1596-8-166/MediaObjects/13000_2013_Article_891_Fig1_HTML.jpg
Figure 1

Immunohistochemical staining of MTA3 in lung cancer tissue sections. a and b: Positive MTA3 staining in a case of lung adenocarcinoma. c and d: Positive MTA3 staining in a case of squamous cell carcinoma.

Table 2

Expression of MTA3 mRNA and protein in the 118 NSCLC cases

Parameter

MTA3 mRNA

MTA3 protein

Expression level

P value

n

P value

Negative

Positive

Gender

  Male

0.2547 ± 0.10485

0.581

24

35

1.000

  Female

0.2442 ± 0.10298

 

24

35

Age (years)

  ≥60

0.2646 ± 0.09439

0.073

21

45

0.038*

  <60

0.2302 ± 0.11224

 

27

25

Histology

  Adeno

0.2444 ± 0.10711

0.534

29

40

0.849

  SCC

0.2565 ± 0.09913

 

19

30

Differentiation

  Well

0.2234 ± 0.11671

0.038*

28

18

0.001*

  Moderate-poor

0.2661 ± 0.09131

 

20

52

Tumor stage

  T1

0.2233 ± 0.10521

 

22

17

0.018*

  T2

0.2485 ± 0.10680

0.030*

21

34

  T3–4

0.2942 ± 0.07934

 

5

19

TNM stage

  I

0.2350 ± 0.10463

0.079

28

24

0.018*

  II

0.2435 ± 0.10970

 

15

27

  III

0.2913 ± 0.08077

 

5

19

Nodal status

  Positive

0.2810 ± 0.08593

0.003*

10

39

0.000*

  Negative

0.2270 ± 0.10969

 

38

31

*Indicated statistical significance (P < 0.05).

Expression level of MTA3 mRNA and protein are risk factors of survival in patients with NSCLC

Survival curves were drawn using SPSS17.0 software with Kaplan-Meier method. Log-rank test indicated that there were significant differences in survival curves between lymph node metastatic group and non-metastatic group (χ2 =22.810, P = 0.000, Figure 2a), among groups of MTA3 protein expression positive and negative (χ2 = 52.161, P = 0.000, Figure 2b), among groups of TNM stage I, II and III (χ2 = 27.037, P = 0.000, Figure 2c) and among groups of tumor status T1, T2 and T3T4 (χ2 = 37.585, P = 0.000, Figure 2d); but no significant differences between male patients and female patients (χ2 = 0.423, P = 0.516, Figure 2e), between ≥60 years old patients and <60 years old patients (χ2 = 2.261, P = 0.133, Figure 2f), between histology types (adeno and SCC) (χ2 = 0.029, P = 0.865, Figure 2g) and between well differentiation and moderate-poor differentiation (χ2 = 2.249, P = 0.134, Figure 2h).
https://static-content.springer.com/image/art%3A10.1186%2F1746-1596-8-166/MediaObjects/13000_2013_Article_891_Fig2_HTML.jpg
Figure 2

Kaplan–Meier curves of the clinical outcome for MTA3 regarding MTA3 immunolabelling. a: Schematic representation shows survival curves of lymph node metastatic group and non-metastatic group in patients with NSCLC (P = 0.000). b: Schematic representation shows survival curves of different MTA3 protein level groups in patients with NSCLC (P = 0.000). c: Schematic representation shows survival curves of different TNM stages in patients with NSCLC (P = 0.000). d: Schematic representation shows survival curves of different tumor stages in patients with NSCLC (P = 0.000). e: Schematic representation shows survival curves of different genders in patients with NSCLC (P = 0.516). f: Schematic representation shows survival curves of different ages in patients with NSCLC (P = 0.133). g: Schematic representation shows survival curves of different histology types in patients with NSCLC (P = 0.865). h: Schematic representation shows survival curves of differentiations in patients with NSCLC (P = 0.134).

Discussion

MTA3 is the latest addition to the MTA family. It was identified as an estrogen-dependent component of the Mi-2/NuRD transcriptional corepressor in breast epithelial cells [8]. Through a MTA3-NuRD complex, MTA3 represses Wnt4 transcription and Wnt4 secretion, inhibiting Wnt-target genes in mammary epithelial cells [18, 19]. The absence of MTA3 as well as the absence of estrogen receptor (ER) results in an aberrantly increased expression of the transcriptional repressor Snail, a master regulator of EMT [2022]. It has also been reported that expression of MTA3 inhibits ductal branching in virgin and pregnant mammary glands in MTA3-transgenic mice [23], where the inappropriate development of mammary glands results in the development of hyperplastic nodules and mammary tumors, including adenocarcinomas and lymphomas [2426]. Considering the many reports showing the clinical relevance of the expression of MTA3, it is likely that MTA3 represents master co-regulatory molecules involved in the carcinogenesis and progression of various malignant tumors.

This study confirmed the presence of MAT3 overexpression in NSCLC samples for the first time. The expression level of MAT3 mRNA and the positive rate of MAT3 protein expression were significantly higher in NSCLC samples (0.2494 ±0.10361 and 59.32%) than that in non-neoplastic samples (0.1578 ± 0.07694 and 0.00%), and in NSCLC samples with lymph node metastasis (49 samples, 0.2810 ± 0.08593) than that in NSCLC samples without lymph node metastasis (69 samples, 0.2270 ± 0.10969) (all P < 0.01). The expression level of MAT3 mRNA was positively correlated with lymph node metastasis, and was a risk factor of lymph node metastasis in the patients with NSCLC (Wald χ2 = 7.493, P = 0.006). There were significant differences in survival curves between lymph node metastatic group and non-metastatic group (χ2 =22.810, P = 0.000), among groups of MAT3 protein expression positive and negative (χ2 = 52.161, P = 0.000), among groups of TNM stage I, II and III (χ2 = 27.037, P = 0.000) and among groups of tumor status T1, T2 and T3T4 (χ2 = 37.585, P = 0.000); but no significant differences between male patients and female patients (χ2 = 0.423, P = 0.516), between ≥60 years old patients and <60 years old patients (χ2 = 2.261, P = 0.133), between histology types (adeno and SCC) (χ2 = 0.029, P = 0.865) and between well differentiation and moderate-poor differentiation (χ2 = 2.249, P = 0.134). The level of MAT3 mRNA and protein were risk factors of survival, but lymph node metastasis was not a risk factor of survival in the patients with NSCLC. These results suggest that there is MAT3 over-expression in NSCLC samples and the level of MAT3 mRNA is a risk factor of lymph node metastasis and survival in the patients with NSCLC. The results may provide a basis for exploring the role of MAT3 in NSCLC. The expression level of MAT3 is expected to become an important index to assess NSCLC invasion and metastasis, and MTA3 may be a useful marker to assess and identify high-risk patients with NSCLC.

Abbreviations

NSCLC: 

Non-small-cell lung cancers

SCC: 

Squamous cell carcinoma

MTA3: 

Metastasis-associated protein 3

BCL6: 

B-cell CLL/lymphoma 6

EMT: 

Epithelial-mesenchymal transition

ER: 

Estrogen receptor.

Declarations

Authors’ Affiliations

(1)
Department of Blood Transfusion, Wuhan General Hospital of Guangzhou Military Command
(2)
College of Basic Medical Sciences, Zhengzhou University
(3)
Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University
(4)
Department of Histology and Embryology, Luohe Medical College

References

  1. Pencil SD, Toh Y, Nicolson GL: Candidate metastasis-associated genes of the rat 13762NF mammary adenocarcinoma. Breast Cancer Res Treat. 1993, 25 (2): 165-174. 10.1007/BF00662141.View ArticlePubMedGoogle Scholar
  2. Toh Y, Pencil SD, Nicolson GL: A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem. 1994, 269 (37): 22958-22963.PubMedGoogle Scholar
  3. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber SL, et al.: Chromatin deacetylation by an ATP-dependent nucleosome remodeling complex. Nature. 1998, 395 (6705): 917-921. 10.1038/27699.View ArticlePubMedGoogle Scholar
  4. Xue Y, Wong J, Moreno GT, Young MK, Cote J, et al.: NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol Cell. 1998, 2 (6): 851-861. 10.1016/S1097-2765(00)80299-3.View ArticlePubMedGoogle Scholar
  5. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, et al.: Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet. 1999, 23 (1): 62-66. 10.1038/12664.View ArticlePubMedGoogle Scholar
  6. Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, et al.: Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 1999, 13 (15): 1924-1935. 10.1101/gad.13.15.1924.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Humphrey GW, Wang Y, Russanova VR, Hirai T, Qin J, et al.: Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J Biol Chem. 2001, 276 (9): 6817-6824. 10.1074/jbc.M007372200.View ArticlePubMedGoogle Scholar
  8. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, et al.: MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 2003, 113 (2): 207-219. 10.1016/S0092-8674(03)00234-4.View ArticlePubMedGoogle Scholar
  9. Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I, et al.: The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther. 2008, 7 (9): 1460-1467. 10.4161/cbt.7.9.6427.View ArticlePubMedGoogle Scholar
  10. Fujita N, Jaye DL, Geigerman C, Akyildiz A, Mooney MR, et al.: MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell. 2004, 119 (1): 75-86. 10.1016/j.cell.2004.09.014.View ArticlePubMedGoogle Scholar
  11. Bruning A, Juckstock J, Blankenstein T, Makovitzky J, Kunze S, et al.: The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas. Histol Histopathol. 2010, 25 (11): 1447-1456.PubMedGoogle Scholar
  12. Zhang H, Stephens LC, Kumar R: Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res. 2006, 12 (5): 1479-1486. 10.1158/1078-0432.CCR-05-1519.View ArticlePubMedGoogle Scholar
  13. Shi Y, Wu H, Zhang M, Ding L, Meng F, Fan X: Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma. Diagn Pathol. 2013, 8: 89-10.1186/1746-1596-8-89.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Mylonas I, Bruning A: The metastasis-associated gene MTA3 is an independent prognostic parameter in uterine non-endometrioid carcinomas. Histopathol. 2012, 60 (4): 665-670. 10.1111/j.1365-2559.2011.04103.x.View ArticleGoogle Scholar
  15. Jemal A, Siegel R, Xu J: Ward E Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.View ArticlePubMedGoogle Scholar
  16. Minna JD, Roth JA, Gazdar AF: Focus on lung cancer. Cancer Cell. 2002, 1 (1): 49-52. 10.1016/S1535-6108(02)00027-2.View ArticlePubMedGoogle Scholar
  17. Xiong Y, Bai Y, Leong N, Laughlin TS, Rothberg PG, Xu H, Nong L, Zhao J, Dong Y, Li T: Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol. 2013, 8: 27-10.1186/1746-1596-8-27.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Lu Q, Lu S, Huang L, Wang T, Wan Y, Zhou C, Zhang C, Zhang Z, Li X: The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer. Diagn Pathol. 2013, 8: 145-10.1186/1746-1596-8-145.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Otto C, Csanadi A, Fisch P, Werner M, Kayser G: Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer. Diagn Pathol. 2012, 7: 146-10.1186/1746-1596-7-146.PubMed CentralView ArticlePubMedGoogle Scholar
  20. Mishra SK, Talukder AH, Gururaj AE, Yang Z, Singh RR, Mahoney MG, Francí C, Vadlamudi RK, Kumar R: Upstream determinants of estrogen receptor-alpha regulation of metastatic tumor antigen 3 pathway. J Biol Chem. 2004, 279 (31): 32709-32715. 10.1074/jbc.M402942200.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Fujita N, Kajita M, Taysavang P, Wade PA: Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Mol Endocrinol. 2004, 18 (12): 2937-2949. 10.1210/me.2004-0258.View ArticlePubMedGoogle Scholar
  22. Chen Y, Miyazaki J, Nishizawa H, Kurahashi H, Leach R, Wang K: MTA3 regulates CGB5 and Snail genes in trophoblast. Biochem Biophys Res Commun. 2013, 433 (4): 379-384. 10.1016/j.bbrc.2013.02.102.PubMed CentralView ArticlePubMedGoogle Scholar
  23. Zhang H, Singh RR, Talukder AH, Kumar R: Metastatic tumor antigen 3 is a direct corepressor of the Wnt4 pathway. Genes Dev. 2006, 20 (21): 2943-2948. 10.1101/gad.1461706.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Bagheri-Yarmand R, Talukder AH, Wang RA, Vadlamudi RK, Kumar R: Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development. 2004, 131 (14): 3469-3479. 10.1242/dev.01213.View ArticlePubMedGoogle Scholar
  25. Manavathi B, Singh K, Kumar R: MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal. 2007, 5: e010-PubMed CentralPubMedGoogle Scholar
  26. Toh Y, Nicolson GL: The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009, 26 (3): 215-227. 10.1007/s10585-008-9233-8.View ArticlePubMedGoogle Scholar

Copyright

© Zheng et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement